RT Journal Article SR Electronic T1 A comparison of therapies using Eyetronix Flicker Glass and standard adhesive patches in children with anisometropic amblyopia: A randomized controlled trial JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.07.20.20157552 DO 10.1101/2020.07.20.20157552 A1 Seung Hyun Min A1 Shijia Chen A1 Jinling Xu A1 Bingzhen Chen A1 Hui Chen A1 Yuwen Wang A1 Jiawei Zhou A1 Xudong Yu YR 2020 UL http://medrxiv.org/content/early/2020/10/26/2020.07.20.20157552.abstract AB Purpose Recently, Eyetronix Flicker Glass (EFG) was introduced as a novel treatment for amblyopia. We conducted a randomized clinical trial to compare the efficacy of the therapies using the Eyetronix Flicker Glass and standard adhesive patches.Methods We tested 31 children (aged 4-13 years) with anisometropic amblyopia. They were assigned into one of the two treatment groups and were treated for 12 weeks. The first group was treated with the Eyetronix Flicker Glass for one hour per day (Flicker Group), and the latter with standard patches (Patching Group) for two hours per day. We considered best-corrected visual acuity (BVCA) of the amblyopic eye after 12 weeks of treatment as the primary outcome. Secondary outcomes were BVCA of the amblyopic at other timepoints of measurement (before the treatment, 3 and 6 weeks) as well as contrast sensitivity of the amblyopic eye, stereopsis and fusion range at all timepoints.Results Visual acuity in the amblyopic eye was significantly improved in both treatment groups at week 12 relative to baseline. The magnitude of improvement was similar. Contrast sensitivity of the amblyopic eye at 3, 6 and 12 cpd was large but not so at 18 cpd for both groups. Stereopsis did not improvement in both groups. However, fusion range significantly improved in the Flicker Group at week 12 relative to baseline.Conclusion After 12 weeks, EFG therapy improves amblyopic eye’s visual acuity, its contrast sensitivity and fusion range of the patients. EFG therapy improves both monocular and binocular functions.Clinical trial registry number ChiCTR2000034436 from the Chinese Clinical Trial RegistryCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000034436Funding StatementThis research was supported by National Natural Science Foundation of China (Grant Nos. 31970975 and 81500754) and the Wenzhou Medical University grant (QTJ16005) to JWZ and Canadian institute of Health Research graduate award to SHM.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research protocol and the informed consent forms were reviewed and approved by the ethics committee of the Affiliated Eye hospital at Wenzhou Medical University (2016-18-Q-11).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData supporting the findings of this study are available from the corresponding author upon request.